The multikinase inhibitor RXDX-105 is effective against neuroblastoma in vitro and in vivo
Flynn S, Lesperance J, Macias A, Phanhthilath N, Paul M, Kim J, Tamayo P, Zage P. The multikinase inhibitor RXDX-105 is effective against neuroblastoma in vitro and in vivo. Oncotarget 2019, 10: 6323-6333. PMID: 31695841, PMCID: PMC6824878, DOI: 10.18632/oncotarget.27259.Peer-Reviewed Original ResearchRXDX-105Small molecule inhibitor of multiple kinasesPediatric cancer-related deathsExtracranial solid tumor of childhoodSolid tumor of childhoodHigh riskHigh-risk neuroblastomaInhibitor of multiple kinasesTumor of childhoodNeuroblastoma in vitroExtracranial solid tumorTreatment of neuroblastoma cellsCancer-related deathsNeuroblastoma cellsRelapsed neuroblastomaRelapsed tumorsMaintenance therapyCell cycle arrestXenograft tumorsTumor growthSmall molecule inhibitorsRas-MAPK pathwayCombined inhibitionRET phosphorylationTumor